Delayed Granulomatous Eruption of the Nose Associated with Ruxolitinib

A 77-year-old woman developed a delayed granulomatous eruption on her nose after 5 years of ruxolitinib treatment for myelofibrosis. Despite various treatments, her condition worsened until ruxolitinib was discontinued, leading to complete resolution within 6 months. This case highlighted the potential for granulomatous drug eruptions (GDEs) associated with JAK inhibitors, emphasizing the need for awareness of such side effects as the use of these drugs increases in dermatology. The patient's granulomatous dermatitis resembled lupus pernio but lacked systemic sarcoidosis signs. The study underscored the importance of documenting JAK inhibitor side effects, given their emerging role in treating various dermatological conditions.